Re: Farmas USA
HALO
Noticias de buena de ayer y palo hoy. ¿Alguien sabe qué supone lo primero dentro de su pipeline?
30-3-17
Modified FOLFIRINOX Will be Temporarily Closed to Enrollment, Unlikely to Demonstrate Statistically Significant Improvement
29-3-17
Halozyme Therapeutics (HALO) Says FDA Committee Provides Unanimous Recommendation For Subcutaneous Rituximab Coformulated With Halozyme Enhanze Technology
voted 11 to 0 that the benefit/risk of rituximab/hyaluronidase for subcutaneous (under the skin) injection was favorable for patients in the proposed indications of follicular lymphoma, diffuse large B-cell lymphoma and chronic lymphocytic leukemia. The FDA action date is June 26, 2017.
«Después de nada, o después de todo/ supe que todo no era más que nada.»